Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.

2.

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.

3.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD.

Clin Exp Metastasis. 2008;25(6):685-93. doi: 10.1007/s10585-007-9121-7. Epub 2008 Jan 31. Review.

4.

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.

5.

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD.

Mol Cancer Ther. 2007 Feb;6(2):532-41.

6.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

7.

Outcome of adult umbilical cord blood transplant patients admitted to a medical intensive care unit.

Naeem N, Eyzaguirre A, Kern JA, Lazarus HM, Hejal RB, Laughlin MJ, Kern EF.

Bone Marrow Transplant. 2006 Dec;38(11):733-8. Epub 2006 Oct 9.

PMID:
17028624

Supplemental Content

Loading ...
Support Center